Dr Severine Roselli Dayas

Dr Severine Roselli Dayas

Postdoctoral Researcher

School of Biomedical Sciences and Pharmacy (Medical Biochemistry)

Career Summary

Biography

Dr Roselli is a researcher in the School of Biomedical Sciences and Pharmacy. Her research interests focus on understanding the molecular mechanisms involved in the pathophysiology of human diseases such as kidney disease and cancer.  Her ultimate research goal is to contribute to the fundamental understanding of these mechanisms in order to identify better treatment strategies for patients. With her combined PhD and post-doctoral experience, she has developed a strong interest in the mechanisms involved in tissue homeostasis, including the interactions between epithelial cells and their environment, and particularly their basement membranes. This applies to all the systems she is interested in; In the kidney glomerulus, the specialized epithelial cells called podocytes together with the glomerular basement membrane are a crucial functional and structural component of the kidney filtration barrier. Podocytes are ‘octopus-like’ mechanosensitive cells composed of a cell body floating in the urinary space and primary processes which divide into actin-rich foot processes, wrapping around the capillary loops and attaching strongly onto the glomerular basement membrane and to each other; thereby forming the ultimate barrier to the passage of blood proteins into the urine. In solid cancers, tumour cells acquire anchorage-independent growth, detach from and invade through the basement membrane in the process of metastasis.

Dr Roselli decided to follow a path towards biomedical research because early on she developed a passion for genetics and hereditary diseases. She completed a PhD in the field of Hereditary kidney disease in France in 2003.  During this work, she participated in the identification of a gene (NPHS2) involved in human hereditary nephrotic syndrome, characterized the protein (podocin) and generated a knockout model of the disease.

 After her PhD, she received a postdoctoral fellowship from the French Foundation for Medical Research (FRM) to undertake post-doctoral training at the world-renowned Sanford-Burnham Medical Research Institute (La Jolla, USA) in order to gain knowledge in cellular signaling, necessary to fully investigate the function of genes and the mechanisms involved in tissue homeostasis. During her post-doc, she also developed a strong interest in cancer research.

Dr Roselli moved to the University of Newcastle (Australia) in 2007 when she was awarded a Cancer Institute NSW ECR fellowship (2007-2010) to investigate the role of the tetraspanin protein CD151 in breast cancer development and metastasisAt UON, she has also developed her own kidney research, based on the special interest and expertise that she developed in glomerular disease and podocyte biology during her PhD. Her laboratory described the importance of CD151 in the glomerular filtration barrier of the kidney and exploited this model to identify putative biomarkers and drug targets of glomerular disease. At Newcastle, Dr Roselli has established state of the art mouse models for the study of breast cancer and kidney disease.

 From April 2012 to February 2015, Dr Roselli worked on several projects with Prof. Hondermarck investigating the value of neurotrophins and their receptors as biomarkers and therapeutic targets in cancer. Since the beginning of 2016, Dr Roselli has teamed up with A/Prof Verrills to study the role of a master regulator of cellular signalling, protein phosphatase 2A (PP2A), in breast cancer. Together they have developed and characterized mouse models of Ppp2r2a (encoding the B55alpha regulatory subunit of PP2A) providing them with a unique tool to investigate the role of B55alpha not only in tumourigenesis but also in development and kidney disease. 


Qualifications

  • Doctor of Philosophy, University of Paris - France

Keywords

  • Podocyte
  • breast cancer
  • cellular and molecular biology
  • genetics
  • kidney glomerular disease
  • mechanisms of disease

Languages

  • English (Fluent)
  • French (Mother)

Fields of Research

Code Description Percentage
060499 Genetics not elsewhere classified 20
110312 Nephrology and Urology 40
111201 Cancer Cell Biology 40

Professional Experience

UON Appointment

Title Organisation / Department
Postdoctoral Researcher University of Newcastle
School of Biomedical Sciences and Pharmacy
Australia
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Journal article (23 outputs)

Year Citation Altmetrics Link
2020 Panicker N, Coutman M, Lawlor-O Neill C, Kahl RGS, Roselli S, Verrills NM, 'Ppp2r2a Knockout Mice Reveal That Protein Phosphatase 2A Regulatory Subunit, PP2A-B55a, Is an Essential Regulator of Neuronal and Epidermal Embryonic Development', Frontiers in Cell and Developmental Biology, 8 (2020)

© Copyright © 2020 Panicker, Coutman, Lawlor-O¿Neill, Kahl, Roselli and Verrills. The serine/threonine protein phosphatase 2A (PP2A) is a master regulator of the complex cellular ... [more]

© Copyright © 2020 Panicker, Coutman, Lawlor-O¿Neill, Kahl, Roselli and Verrills. The serine/threonine protein phosphatase 2A (PP2A) is a master regulator of the complex cellular signaling that occurs during all stages of mammalian development. PP2A is composed of a catalytic, a structural, and regulatory subunit, for which there are multiple isoforms. The association of specific regulatory subunits determines substrate specificity and localization of phosphatase activity, however, the precise role of each regulatory subunit in development is not known. Here we report the generation of the first knockout mouse for the Ppp2r2a gene, encoding the PP2A-B55a regulatory subunit, using CRISPR/Cas9. Heterozygous animals developed and grew as normal, however, homozygous knockout mice were not viable. Analysis of embryos at different developmental stages found a normal Mendelian ratio of Ppp2r2a¿/¿ embryos at embryonic day (E) 10.5 (25%), but reduced Ppp2r2a¿/¿ embryos at E14.5 (18%), and further reduced at E18.5 (10%). No live Ppp2r2a¿/¿ pups were observed at birth. Ppp2r2a¿/¿ embryos were significantly smaller than wild-type or heterozygous littermates and displayed a variety of neural defects such as exencephaly, spina bifida, and cranial vault collapse, as well as syndactyly and severe epidermal defects; all processes driven by growth and differentiation of the ectoderm. Ppp2r2a¿/¿ embryos had incomplete epidermal barrier acquisition, associated with thin, poorly differentiated stratified epithelium with weak attachment to the underlying dermis. The basal keratinocytes in Ppp2r2a¿/¿ embryos were highly disorganized, with reduced immunolabeling of integrins and basement membrane proteins, suggesting impaired focal adhesion and hemidesmosome assembly. The spinous and granular layers were thinner in the Ppp2r2a¿/¿ embryos, with aberrant expression of adherens and tight junction associated proteins. The overlying stratum corneum was either absent or incomplete. Thus PP2A-B55a is an essential regulator of epidermal stratification, and is essential for ectodermal development during embryogenesis.

DOI 10.3389/fcell.2020.00358
2020 Bond DR, Kahl R, Brzozowski JS, Jankowski H, Naudin C, Pariyar M, et al., 'Tetraspanin CD9 is regulated by MiR-518f-5p and functions in breast cell migration and in vivo tumor growth', Cancers, 12 (2020) [C1]
DOI 10.3390/cancers12040795
Co-authors Danielle Bond, Murray Cairns, C Scarlett, Judith Weidenhofer, Kelly Kiejda, Leonie Ashman
2018 Gao F, Griffin N, Faulkner S, Rowe CW, Williams L, Roselli S, et al., 'The neurotrophic tyrosine kinase receptor TrkA and its ligand NGF are increased in squamous cell carcinomas of the lung', SCIENTIFIC REPORTS, 8 (2018) [C1]
DOI 10.1038/s41598-018-26408-2
Citations Scopus - 6Web of Science - 4
Co-authors Christopher W Rowe, Phillip Jobling, Rick Thorne, Hubert Hondermarck, Sam Faulkner, Marjorie Walker
2018 Faulkner S, Jobling P, Rowe CW, Rodrigues Oliveira SM, Roselli S, Thorne RF, et al., 'Neurotrophin Receptors TrkA, p75

© 2018 American Society for Investigative Pathology Neurotrophin receptors are emerging targets in oncology, but their clinicopathologic significance in thyroid cancer is unclear.... [more]

© 2018 American Society for Investigative Pathology Neurotrophin receptors are emerging targets in oncology, but their clinicopathologic significance in thyroid cancer is unclear. In this study, the neurotrophin tyrosine receptor kinase TrkA (also called NTRK1), the common neurotrophin receptor p75NTR, and the proneurotrophin receptor sortilin were analyzed with immunohistochemistry in a cohort of thyroid cancers (n = 128) and compared with adenomas and normal thyroid tissues (n = 62). TrkA was detected in 20% of thyroid cancers, compared with none of the benign samples (P = 0.0007). TrkA expression was independent of histologic subtypes but associated with lymph node metastasis (P = 0.0148), suggesting the involvement of TrkA in tumor invasiveness. Nerves in the tumor microenvironment were positive for TrkA. p75NTR was overexpressed in anaplastic thyroid cancers compared with papillary and follicular subtypes (P < 0.0001). Sortilin was overexpressed in thyroid cancers compared with benign thyroid tissues (P < 0.0001). Neurotrophin receptor expression was confirmed in a panel of thyroid cancer cell lines at the mRNA and protein levels. Functional investigations using the anaplastic thyroid cancer cell line CAL-62 found that siRNA against TrkA, p75NTR, and sortilin decreased cell survival and cell migration through decreased SRC and ERK activation. Together, these data reveal TrkA, p75NTR, and sortilin as potential therapeutic targets in thyroid cancer.

DOI 10.1016/j.ajpath.2017.09.008
Citations Scopus - 12Web of Science - 9
Co-authors Xu Zhang, Chenchen Jiang, Sam Faulkner, John Attia, Marjorie Walker, Hubert Hondermarck, Rick Thorne, Phillip Jobling, Christopher W Rowe, Christopher Oldmeadow
2017 Watt LF, Panicker N, Mannan A, Copeland B, Kahl RGS, Dun MD, et al., 'Functional importance of PP2A regulatory subunit loss in breast cancer', Breast Cancer Research and Treatment, 166 117-131 (2017) [C1]

© 2017, Springer Science+Business Media, LLC. Purpose: Protein phosphatase 2A (PP2A) is a family of serine/threonine phosphatases that regulate multiple cellular signalling pathwa... [more]

© 2017, Springer Science+Business Media, LLC. Purpose: Protein phosphatase 2A (PP2A) is a family of serine/threonine phosphatases that regulate multiple cellular signalling pathways involved in proliferation, survival and apoptosis. PP2A inhibition occurs in many cancers and is considered a tumour suppressor. Deletion/downregulation of PP2A genes has been observed in breast tumours, but the functional role of PP2A subunit loss in breast cancer has not been investigated. Methods: PP2A subunit expression was examined by immunohistochemistry in human breast tumours, and by qPCR and immunoblotting in breast cancer cell lines. PP2A subunits were inhibited by shRNA, and mutant PP2A genes overexpressed, in MCF10A and MCF7 cells, and growth and signalling in standard and three-dimensional cultures were assessed. Results: Expression of PP2A-Aa, PP2A-Ba and PP2A-B'a subunits was significantly lower in primary human breast tumours and lymph node metastases, compared to normal mammary tissue. PP2A-Aa and the regulatory subunits PP2A-Ba, -Bd and -B'¿ were also reduced in breast cancer cell lines compared to normal mammary epithelial cells. Functionally, shRNA-mediated knockdown of PP2A-Ba, -B'a and -B'¿, but not PP2A-Aa, induced hyper-proliferation and large multilobular acini in MCF10A 3D cultures, characterised by activation of ERK. Expression of a breast cancer-associated PP2A-A mutant, PP2A-Aa-E64G, which inhibits binding of regulatory subunits to the PP2A core, induced a similar hyper-proliferative phenotype. Knockdown of PP2A-Ba also induced hyper-proliferation in MCF7 breast cancer cells. Conclusion: These results suggest that loss of specific PP2A regulatory subunits is functionally important in breast tumourigenesis, and support strategies to enhance PP2A activity as a therapeutic approach in breast cancer.

DOI 10.1007/s10549-017-4403-5
Citations Scopus - 8Web of Science - 8
Co-authors Matt Dun, Nikki Verrills
2017 Naudin C, Smith B, Bond DR, Dun MD, Scott RJ, Ashman LK, et al., 'Characterization of the early molecular changes in the glomeruli of Cd151 -/- mice highlights induction of mindin and MMP-10.', Scientific Reports, 7 15987-15987 (2017) [C1]
DOI 10.1038/s41598-017-15993-3
Citations Scopus - 5Web of Science - 4
Co-authors Danielle Bond, Matt Dun, Leonie Ashman, Rodney Scott, Judith Weidenhofer
2016 Faulkner S, Roselli S, Demont Y, Pundavela J, Choquet G, Leissner P, et al., 'ProNGF is a potential diagnostic biomarker for thyroid cancer', Oncotarget, 7 28488-28497 (2016) [C1]

The precursor for nerve growth factor (proNGF) is expressed in some cancers but its clinicopathological significance is unclear. The present study aimed to define the clinicopatho... [more]

The precursor for nerve growth factor (proNGF) is expressed in some cancers but its clinicopathological significance is unclear. The present study aimed to define the clinicopathological significance of proNGF in thyroid cancer. ProNGF expression was analysed by immunohistochemistry in two cohorts of cancer versus benign tumors (adenoma) and normal thyroid tissues. In the first cohort (40 thyroid cancers, 40 thyroid adenomas and 80 normal thyroid tissues), proNGF was found overexpressed in cancers compared to adenomas and normal samples (p<0.0001). The area under the receiver-operating characteristic (ROC) curve was 0.84 (95% CI 0.75-0.93, p<0.0001) for cancers versus adenomas, and 0.99 (95% CI 0.98-1.00, p<0.0001) for cancers versus normal tissues. ProNGF overexpression was confirmed in a second cohort (127 cancers of various histological types and 55 normal thyroid tissues) and using a different antibody (p<0.0001). ProNGF staining intensity was highest in papillary carcinomas compared to other histological types (p<0.0001) and there was no significant association with age, gender, tumor size, stage and lymph node status. In conclusion, proNGF is increased in thyroid cancer and should be considered as a new potential diagnostic biomarker.

DOI 10.18632/oncotarget.8652
Citations Scopus - 13Web of Science - 13
Co-authors Marjorie Walker, John Attia, Sam Faulkner, Hubert Hondermarck, Christopher Oldmeadow
2015 Roselli S, Pundavela J, Demont Y, Faulkner S, Keene S, Attia J, et al., 'Sortilin is associated with breast cancer aggressiveness and contributes to tumor cell adhesion and invasion', Oncotarget, 6 10473-10486 (2015) [C1]

The neuronal membrane protein sortilin has been reported in a few cancer cell lines, but its expression and impact in human tumors is unclear. In this study, sortilin was analyzed... [more]

The neuronal membrane protein sortilin has been reported in a few cancer cell lines, but its expression and impact in human tumors is unclear. In this study, sortilin was analyzed by immunohistochemistry in a series of 318 clinically annotated breast cancers and 53 normal breast tissues. Sortilin was detected in epithelial cells, with increased levels in cancers, as compared to normal tissues (p = 0.0088). It was found in 79% of invasive ductal carcinomas and 54% of invasive lobular carcinomas (p < 0.0001). There was an association between sortilin expression and lymph node involvement (p = 0.0093), suggesting a relationship with metastatic potential. In cell culture, sortilin levels were higher in cancer cell lines compared to non-tumorigenic breast epithelial cells and siRNA knockdown of sortilin inhibited cancer cell adhesion, while proliferation and apoptosis were not affected. Breast cancer cell migration and invasion were also inhibited by sortilin knockdown, with a decrease in focal adhesion kinase and SRC phosphorylation. In conclusion, sortilin participates in breast tumor aggressiveness and may constitute a new therapeutic target against tumor cell invasion.

DOI 10.18632/oncotarget.3401
Citations Scopus - 22Web of Science - 20
Co-authors Marjorie Walker, Sam Faulkner, John Attia, Chenchen Jiang, Xu Zhang, Hubert Hondermarck
2015 Jobling P, Pundavela J, Oliveira SMR, Roselli S, Walker MM, Hondermarck H, 'Nerve-Cancer Cell Cross-talk: A Novel Promoter of Tumor Progression', CANCER RESEARCH, 75 1777-1781 (2015) [C1]
DOI 10.1158/0008-5472.CAN-14-3180
Citations Scopus - 93Web of Science - 84
Co-authors Marjorie Walker, Hubert Hondermarck, Phillip Jobling
2015 Pundavela J, Roselli S, Faulkner S, Attia J, Scott RJ, Thorne RF, et al., 'Nerve fibers infiltrate the tumor microenvironment and are associated with nerve growth factor production and lymph node invasion in breast cancer', Molecular Oncology, 9 1626-1635 (2015) [C1]
DOI 10.1016/j.molonc.2015.05.001
Citations Scopus - 31Web of Science - 27
Co-authors Marjorie Walker, John Attia, Sam Faulkner, Hubert Hondermarck, Rodney Scott, Phillip Jobling, Rick Thorne
2014 Pundavela J, Demont Y, Jobling P, Lincz LF, Roselli S, Thorne RF, et al., 'ProNGF correlates with Gleason score and is a potential driver of nerve infiltration in prostate cancer', American Journal of Pathology, 184 3156-3162 (2014) [C1]

© 2014 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved. Nerve infiltration is essential to prostate cancer progression, but the mechan... [more]

© 2014 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved. Nerve infiltration is essential to prostate cancer progression, but the mechanism by which nerves are attracted to prostate tumors remains unknown. We report that the precursor of nerve growth factor (proNGF) is overexpressed in prostate cancer and involved in the ability of prostate cancer cells to induce axonogenesis. A series of 120 prostate cancer and benign prostate hyperplasia (BPH) samples were analyzed by IHC for proNGF. ProNGF was mainly localized in the cytoplasm of epithelial cells, with marked expression in cancer compared with BPH. Importantly, the proNGF level positively correlated with the Gleason score (n = 104, t<inf>B</inf> = 0.51). A higher level of proNGF was observed in tumors with a Gleason score of =8 compared with a Gleason score of 7 and 6 (P < 0.001). In vitro, proNGF was detected in LNCaP, DU145, and PC-3 prostate cancer cells and BPH-1 cells but not in RWPE-1 immortalized nontumorigenic prostate epithelial cells or primary normal prostate epithelial cells. Co-culture of PC12 neuronal-like cells or 50B11 neurons with PC-3 cells resulted in neurite outgrowth in neuronal cells that was inhibited by blocking antibodies against proNGF, indicating that prostate cancer cells can induce axonogenesis via secretion of proNGF. These data reveal that ProNGF is a biomarker associated with high-risk prostate cancers and a potential driver of infiltration by nerves.

DOI 10.1016/j.ajpath.2014.08.009
Citations Scopus - 37Web of Science - 33
Co-authors Danielle Bond, Lisa Lincz, Marjorie Walker, Hubert Hondermarck, Rick Thorne, Phillip Jobling
2014 Roselli S, Kahl RGS, Copeland BT, Naylor MJ, Weidenhofer J, Muller WJ, Ashman LK, 'Deletion of Cd151 reduces mammary tumorigenesis in the MMTV/PyMT mouse model', BMC Cancer, 14 (2014) [C1]

Background: Tetraspanins are transmembrane proteins that serve as scaffolds for multiprotein complexes containing, for example, integrins, growth factor receptors and matrix metal... [more]

Background: Tetraspanins are transmembrane proteins that serve as scaffolds for multiprotein complexes containing, for example, integrins, growth factor receptors and matrix metalloproteases, and modify their functions in cell adhesion, migration and transmembrane signaling. CD151 is part of the tetraspanin family and it forms tight complexes with ß1 and ß4 integrins, both of which have been shown to be required for tumorigenesis and/or metastasis in transgenic mouse models of breast cancer. High levels of the tetraspanin CD151 have been linked to poor patient outcome in several human cancers including breast cancer. In addition, CD151 has been implicated as a promoter of tumor angiogenesis and metastasis in various model systems.Methods: Here we investigated the effect of Cd151 deletion on mammary tumorigenesis by crossing Cd151-deficient mice with a spontaneously metastasising transgenic model of breast cancer induced by the polyoma middle T antigen (PyMT) driven by the murine mammary tumor virus promoter (MMTV).Results: Cd151 deletion did not affect the normal development and differentiation of the mammary gland. While there was a trend towards delayed tumor onset in Cd151 -/- PyMT mice compared to Cd151 +/+ PyMT littermate controls, this result was only approaching significance (Log-rank test P-value =0.0536). Interestingly, Cd151 deletion resulted in significantly reduced numbers and size of primary tumors but did not appear to affect the number or size of metastases in the MMTV/PyMT mice. Intriguingly, no differences in the expression of markers of cell proliferation, apoptosis and blood vessel density was observed in the primary tumors.Conclusion: The findings from this study provide additional evidence that CD151 acts to enhance tumor formation initiated by a range of oncogenes and strongly support its relevance as a potential therapeutic target to delay breast cancer progression. © 2014 Roselli et al.; licensee BioMed Central Ltd.

DOI 10.1186/1471-2407-14-509
Citations Scopus - 10Web of Science - 12
Co-authors Leonie Ashman, Judith Weidenhofer
2014 Bond DB, Brzozowski J, Skelding KA, Roselli SR, Weidenhofer J, 'Use of tetraspanins CD151 and CD9 as biomarkers for breast cancer', Breast Cancer Management, 3 123-126 (2014) [C3]
DOI 10.2217/bmt.14.2
Co-authors Danielle Bond, Judith Weidenhofer, Kathryn Skelding
2010 Roselli SM, Wallez Y, Wang L, Vervoort V, Pasquale EB, 'The SH2 domain protein Shep1 regulates the in vivo signaling function of the scaffolding protein Cas', Cellular Signalling, 22 1745-1752 (2010) [C1]
DOI 10.1016/j.cellsig.2010.06.015
Citations Scopus - 11Web of Science - 9
2008 Baleato R, Guthrie PL, Gubler M-C, Ashman LK, Roselli SM, 'Deletion of Cd151 results in a strain-dependent glomerular disease due to severe alterations of the glomerular basement membrane', American Journal of Pathology, 173 927-937 (2008) [C1]
DOI 10.2353/ajpath.2008.071149
Citations Scopus - 82Web of Science - 74
Co-authors Leonie Ashman
2007 Vervoort VS, Roselli S, Oshima RG, Pasquale EB, 'Splice variants and expression patterns of SHEP1, BCAR3 and NSP1, a gene family involved in integrin and receptor tyrosine kinase signaling.', Gene, 391 161-170 (2007) [C1]
DOI 10.1016/j.gene.2006.12.016
Citations Scopus - 11Web of Science - 11
2004 Roselli S, Heidet L, Sich M, Henger A, Kretzler M, Gubler MC, Antignac C, 'Early glomerular filtration defect and severe renal disease in podocin-deficient mice', Molecular and Cellular Biology, 24 550-560 (2004) [C1]
DOI 10.1128/MCB.24.2.550-560.2004
Citations Scopus - 206Web of Science - 188
2004 Roselli S, Moutkine I, Gribouval O, Benmerah A, Antignac C, 'Plasma Membrane Targeting of Podocin Through the Classical Exocytic Pathway: Effect of NPHS2 Mutations.', Traffic, 5 37-44 (2004) [C1]
DOI 10.1046/j.1600-0854.2003.00148.x
Citations Scopus - 72Web of Science - 65
2002 Boute N, Roselli S, Gribouval O, Niaudet P, Gubler MC, Antignac C, 'Characterization of the NPHS2 gene, encoding for the glomerular protein podocin, involved in a familiar form of steroid-resistant nephrotic syndrome', NEPHROLOGIE, 23 35-36 (2002)
Citations Scopus - 3Web of Science - 4
2002 Boute N, Roselli S, Gribouval O, Niaudet P, Gubler M-C, Antignac C, '[Characterization of the NPH2 gene, coding for the glomerular protein podocin, implicated in a familial form of cortico-resistant nephrotic syndrome transmitted as an autosomal recessive].', Nephrologie, 23 35-36 (2002)
2002 Roselli S, Sich M, Gubler MC, Antignac C, 'Mice lacking podocin develop a severe glomerular disease.', JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 13 17A-17A (2002)
Citations Web of Science - 2
2002 Roselli S, Gribouval O, Boute N, Sich M, Benessy F, Attie T, et al., 'Podocin localizes in the kidney to the slit diaphragm area', American Journal of Pathology, 160 131-139 (2002) [C1]
Citations Scopus - 239Web of Science - 230
2000 Boute N, Gribouval O, Roselli S, Benessy F, Lee H, Fuchshuber A, et al., 'NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome.', Nature Genetics, 24 349-354 (2000) [C1]
Citations Scopus - 1094Web of Science - 1015
Show 20 more journal articles

Conference (25 outputs)

Year Citation Altmetrics Link
2019 Chen Y, AlMazi J, Murray H, Mannan A, Panicker N, Roselli S, et al., 'Phosphoproteomics Uncovers Signalling Pathways Modulated by PP2A B55 alpha in Breast Cancer', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2019)
Co-authors Nikki Verrills, Matt Dun
2019 Coutman M, Panicker N, Kahl R, Roselli S, Verrills N, 'The Role of the Tumour Suppressor PP2A-B55 alpha in Epidermal Development', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2019)
2018 Panicker N, Roselli S, Kahl R, Watt L, Coutman M, Mannan A, Verrills N, 'Targeting the Tumor Suppressor PP2A-B55 alpha as a Therapeutic Strategy for Poor Prognosis Breast Cancer', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2018)
Co-authors Nikki Verrills
2018 Panicker N, Roselli S, Kahl R, Mannan A, Watt L, Verrills N, 'From mammalian development to breast cancer: All roads lead to Protein Phosphatase 2A', EUROPEAN JOURNAL OF CANCER, Barcelona, SPAIN (2018)
2018 Mannan A, Roselli S, Kahl RGS, Skelding K, Dun M, Verrills N, 'Loss of Protein Phosphatase 2A Regulatory Subunit B55 alpha Enhances Tumor Progression and Tamoxifen Resistance in Luminal Breast Cancer', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2018)
Co-authors Nikki Verrills, Matt Dun, Kathryn Skelding
2018 Gao F, Griffin N, Faulkner S, Rowe CW, Williams L, Roselli S, Thorne RF, 'The Neurotrophic Tyrosine Kinase Receptor TrkA and Its Ligand NGF are Increased in Squamous Cell Carcinomas of the Lung', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2018)
Co-authors Sam Faulkner, Rick Thorne, Christopher W Rowe
2018 Verrills N, Mannan A, Panicker N, Chen Y, Coutman M, Murray H, et al., 'Translating Fundamental Biology into a New Treatment for Therapy-Resistant Breast Cancer: Bench to Bedside and (almost) Back Again!', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2018)
Co-authors Matt Dun, Nikki Verrills, Heather Murray
2017 Panicker N, Roselli S, Kahl R, Watt L, Verrills N, 'The Encompassing Role of Tumor Suppressive Phosphatase in Mammalian Development and Cancer', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2017)
Co-authors Nikki Verrills
2017 Panicker N, Mannan A, Watt LF, Copeland B, Dun MD, King S, et al., 'Functional role of the tumor suppressor protein phosphatase, PP2A-B55 alpha, in breast cancer', CANCER RESEARCH, Washington, DC (2017)
DOI 10.1158/1538-7445.AM2017-2375
Co-authors Matt Dun, Nikki Verrills, Kathryn Skelding
2016 Faulkner S, Jobling P, Rowe C, Oldmeadow C, Roselli S, Thorne R, et al., 'CLINICOPATHOLOGICAL SIGNIFICANCE OF PRONGF RECEPTORS IN THYROID CANCER', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2016)
Co-authors Christopher W Rowe, Phillip Jobling, Hubert Hondermarck, Rick Thorne, Christopher Oldmeadow, Marjorie Walker, John Attia
2016 Panicker N, Roselli S, Kahl R, Watt L, Flynn J, Verrills N, 'PPP2R2A LOSS AND ITS ROLE IN GROWTH, DEVELOPMENT, AND BREAST CANCER', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2016)
2016 Oliveira SMR, Roselli S, Hondermarck H, Jobling P, 'OVARIAN TUMORS PRESENT AUTONOMIC AND SENSORY INNERVATION', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2016)
Co-authors Hubert Hondermarck, Phillip Jobling
2015 Watt LF, Panicker N, Copeland B, Kahl RGS, Dun MD, Young B, et al., 'PP2A a novel biomarker and therapeutic target for poor outcome breast cancer', Proceedings of the Lowy Cancer Conference, Sydney (2015) [E3]
Co-authors Matt Dun, Nikki Verrills, Kathryn Skelding
2015 Pundavela J, Roselli S, Demont Y, Faulkner S, Attia J, Keene S, et al., 'The neuronal protein sortilin is expressed in aggressive breast cancers and participates in tumor cell growth and invasion', CANCER RESEARCH, San Antonio, TX (2015) [E3]
DOI 10.1158/1538-7445.SABCS14-P6-01-11
Co-authors Hubert Hondermarck, Sam Faulkner, John Attia, Marjorie Walker
2015 Oliveira S, Roselli S, Hondermarck H, Jobling P, 'Nerve fibers infiltrate ovarian cancer and may be related to tumor aggressiveness', JOURNAL OF NEUROCHEMISTRY, Cairns, AUSTRALIA (2015) [E3]
Co-authors Hubert Hondermarck, Phillip Jobling
2015 Naudin C, Weidenhofer J, Roselli S, Keely S, 'Induction of Mindin is Associated with Pathological Changes in the Kidney of Cd151(-/-) Mice', FASEB JOURNAL (2015) [E3]
Co-authors Judith Weidenhofer, Simon Keely
2015 Faulkner S, Roselli S, Demont Y, Choquet G, Leissner P, Oldmeadow C, et al., 'ProNGF AS A NEW BIOMARKER IN THYROID CANCER', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
Co-authors Hubert Hondermarck, Christopher Oldmeadow, Sam Faulkner, Marjorie Walker, John Attia
2014 Faulkner S, Roselli S, Thorne RF, Scarlett CJ, Walker MM, Hondermarck H, 'PRONGF AND SORTILIN EXPRESSION AND FUNCTION IN PANCREATIC CANCER', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Citations Web of Science - 1
Co-authors Marjorie Walker, Sam Faulkner, Hubert Hondermarck, Rick Thorne, C Scarlett
2014 Oliveira SMR, Roselli S, Hondermarck H, Jobling P, 'PERIPHERAL NERVES ARE ASSOCIATED WITH SOME OVARIAN TUMOURS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Co-authors Phillip Jobling, Hubert Hondermarck
2012 Roselli SM, Moscato PA, Scott R, Hondermarck H, 'Breast cancer proteomics: Integrating the data with genomics and histology towards clinical applications', 18th Proteomics Symposium. Delegate Handbook, Lorne, Vic (2012) [E3]
Co-authors Hubert Hondermarck, Pablo Moscato, Rodney Scott
2011 Naudin C, Weidenhofer JC, Scott R, Ashman LK, Roselli SM, 'Induction of mindin expression is associated with glomerular basement membrane damage in Cd151(-/-) mice', Nephrology, Adelaide, SA (2011) [E3]
Co-authors Judith Weidenhofer, Leonie Ashman, Rodney Scott
2008 Baleato RM, Guthrie PL, Gubler M-C, Ashman LK, Roselli S, 'CD151-DEFICIENT MICE DEVELOP A STRAIN-DEPENDENT KIDNEY DISEASE DUE TO ALTERATIONS OF THE GLOMERULAR BASEMENT MEMBRANE', NEPHROLOGY (2008) [E3]
Co-authors Leonie Ashman
2003 Zhang SY, Roselli S, Antignac C, Gubler MC, 'Expression of podocin and related proteins in steroid resistant nephrotic syndrome due to NPHS2 mutations.', JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, SAN DIEGO, CALIFORNIA (2003)
2003 Morita H, Yoshimura A, Inui K, Matsuyama M, Roselli S, Antignac C, Ideura T, 'Rat podocin expression in experimental and congenital models showing proteinuria.', JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, SAN DIEGO, CALIFORNIA (2003)
2002 Roselli S, Sich M, Gubler MC, Antignac C, 'Mice lacking podocin develop a severe glomerular phenotype.', AMERICAN JOURNAL OF HUMAN GENETICS, BALTIMORE, MARYLAND (2002)
Show 22 more conferences
Edit

Grants and Funding

Summary

Number of grants 16
Total funding $1,609,815

Click on a grant title below to expand the full details for that specific grant.


20191 grants / $4,500

Kyratec PCR machine$4,500

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Associate Professor Nikki Verrills, Doctor Severine Roselli Dayas, Doctor Matt Dun
Scheme Early and Mid-Career Equipment Grant
Role Investigator
Funding Start 2019
Funding Finish 2019
GNo G1900111
Type Of Funding C3120 - Aust Philanthropy
Category 3120
UON Y

20182 grants / $29,141

A new approach for treating therapy resistant breast cancer$25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Severine Roselli Dayas, Associate Professor Nikki Verrills, Doctor Nick Zdenkowski, Dr James Lynam
Scheme Project Grant
Role Lead
Funding Start 2018
Funding Finish 2018
GNo G1801453
Type Of Funding C3120 - Aust Philanthropy
Category 3120
UON Y

Jennie Thomas Medical Research Travel Grant - Nikita Panicker$4,141

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Miss Nikita Panicker, Associate Professor Nikki Verrills, Doctor Severine Roselli Dayas, Doctor Matt Dun
Scheme Jennie Thomas Medical Research Travel Grant
Role Investigator
Funding Start 2018
Funding Finish 2018
GNo G1800024
Type Of Funding C3120 - Aust Philanthropy
Category 3120
UON Y

20171 grants / $24,000

Targeting a tumour suppressor for new cancer therapies $24,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Associate Professor Nikki Verrills, Doctor Matt Dun, Doctor Severine Roselli Dayas
Scheme Project Grant
Role Investigator
Funding Start 2017
Funding Finish 2018
GNo G1700588
Type Of Funding C3120 - Aust Philanthropy
Category 3120
UON Y

20141 grants / $20,000

Prostate Cancer: A new protein for improving diagnosis, prognosis and treatment$20,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Severine Roselli Dayas, Professor Hubert Hondermarck
Scheme Project Grant
Role Lead
Funding Start 2014
Funding Finish 2014
GNo G1401520
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

20131 grants / $24,596

20121 grants / $34,000

Microscopic illumination system for advanced fluorescent protein technology$34,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Doctor Rick Thorne, Professor Xu Dong Zhang, Professor Murray Cairns, Associate Professor Nikki Verrills, Doctor Charles De Bock, Doctor Jude Weidenhofer, Doctor Severine Roselli Dayas, Associate Professor Kathryn Skelding, Emeritus Professor Leonie Ashman, Professor Hubert Hondermarck
Scheme Equipment Grant
Role Investigator
Funding Start 2012
Funding Finish 2012
GNo G1100983
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

20112 grants / $35,000

Investigation of the function of CD151 in the glomerular filtration barrier and identification of genetic modifiers of glomerular diseases$25,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Doctor Severine Roselli Dayas, Doctor Jude Weidenhofer, Emeritus Professor Leonie Ashman
Scheme Near Miss Grant
Role Lead
Funding Start 2011
Funding Finish 2011
GNo G1001053
Type Of Funding Internal
Category INTE
UON Y

IMPLEN NanoPhotometer pearl$10,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Murray Cairns, Associate Professor Paul Tooney, Professor Alan Brichta, Emeritus Professor John Rostas, Emeritus Professor Patricia Michie, Conjoint Professor Keith Jones, Professor Ulli Schall, Associate Professor Phillip Dickson, Professor Rohan Walker, Doctor Rick Thorne, Professor Chris Dayas, Associate Professor Nikki Verrills, Doctor Janet Bristow, Doctor Severine Roselli Dayas, Associate Professor Kathryn Skelding, Doctor Jude Weidenhofer, Professor Liz Milward, Doctor Charles De Bock, Doctor Julie Merriman-Jones, Doctor Jing Qin Wu, Doctor Bing Liu, Dr DAN Johnstone, Ms Belinda Goldie, Doctor Natalie Beveridge
Scheme Equipment Grant
Role Investigator
Funding Start 2011
Funding Finish 2011
GNo G1100030
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

20101 grants / $34,000

ABI 7500 Real Time PCR System $34,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Doctor Rick Thorne, Associate Professor Nikki Verrills, Professor Murray Cairns, Associate Professor Paul Tooney, Associate Professor Doug Smith, Professor Gordon Burns, Emeritus Professor Leonie Ashman, Conjoint Professor Keith Jones, Doctor Charles De Bock, Professor Chris Dayas, Associate Professor Brett Graham, Doctor Martin Horan, Associate Professor Rebecca Lim, Doctor Severine Roselli Dayas, Doctor Larisa Bobrovskaya, Associate Professor Kathryn Skelding, Professor Rohan Walker, Doctor Jude Weidenhofer, Conjoint Professor Philip Bolton, Professor Alan Brichta, Conjoint Professor Robert Callister, Professor Trevor Day, Associate Professor Phillip Dickson, Professor Manohar Garg, Associate Professor Phil Jobling, Professor Derek Laver, Associate Professor Eugene Nalivaiko, Emeritus Professor John Rostas
Scheme Equipment Grant
Role Investigator
Funding Start 2010
Funding Finish 2010
GNo G1000055
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

20094 grants / $775,000

FACSAria$30,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Doctor Rick Thorne, Doctor Severine Roselli Dayas, Professor Xu Dong Zhang, Dr Charles De Bock, Conjoint Professor Peter Hersey, Professor Gordon Burns
Scheme Equipment Grant
Role Investigator
Funding Start 2009
Funding Finish 2009
GNo G0189846
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

Identification of genetic modifiers of kidney disease$25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Severine Roselli Dayas, Emeritus Professor Leonie Ashman, Laureate Professor Rodney Scott
Scheme Project Grant
Role Lead
Funding Start 2009
Funding Finish 2009
GNo G0189793
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

20081 grants / $75,000

Role of tetraspanin proteins in human breast and prostate cancer$75,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Emeritus Professor Leonie Ashman, Doctor Severine Roselli Dayas
Scheme Mary Minto Sawyer Grant
Role Investigator
Funding Start 2008
Funding Finish 2010
GNo G0188187
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

20071 grants / $554,578

Murine models to determine the role of the tetraspanin CD151 in epithelial tumour initiation and progression$554,578

Funding body: Cancer Institute NSW

Funding body Cancer Institute NSW
Project Team Doctor Severine Roselli Dayas
Scheme Career Development Fellowship
Role Lead
Funding Start 2007
Funding Finish 2009
GNo G0186974
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y
Edit

Research Supervision

Number of supervisions

Completed5
Current1

Current Supervision

Commenced Level of Study Research Title Program Supervisor Type
2016 PhD Reduced Expression of Protein Phosphatase 2A Subunit, PPP2R2A and its Role in Breast Cancer PhD (Medical Biochemistry), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor

Past Supervision

Year Level of Study Research Title Program Supervisor Type
2018 PhD ProNGF, NGF and their Receptors in Tumour Innervation and Progression: a Study in Breast and Thyroid Cancers PhD (Medical Biochemistry), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
2018 PhD The Nerve-Cancer Connection in Ovarian Cancer PhD (Human Physiology), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
2015 PhD The Tetraspanin CD151's Role in the Kidney and Mapping of Genetic Modifiers of Glomerular Diseases PhD (Medical Biochemistry), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
2013 PhD Tetraspanins as Biomarkers and Causative Proteins in Prostate Cancer PhD (Medical Biochemistry), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
2012 PhD The Role of Protein Phosphatase 2A as a Tumour Suppressor in Breast Cancer PhD (Medical Biochemistry), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
Edit

Dr Severine Roselli Dayas

Position

Postdoctoral Researcher
School of Biomedical Sciences and Pharmacy
Faculty of Health and Medicine

Focus area

Medical Biochemistry

Contact Details

Email severine.roselli@newcastle.edu.au
Phone (02) 4921 5915
Fax (02) 4921 6903

Office

Room LS3-37
Building Life Sciences
Location Callaghan
University Drive
Callaghan, NSW 2308
Australia
Edit